Open AccessSurvival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
Author(s) -
Danielle M. Bello,
Katherine S. Panageas,
Travis J. Hollmann,
Alexander N. Shoushtari,
Parisa Momtaz,
Paul B. Chapman,
Michael A. Postow,
Margaret K. Callahan,
Jedd D. Wolchok,
Mary Sue Brady,
Daniel G. Coit,
Charlotte E. Ariyan
Publication year - 2019
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-08099-9
Subject(s) - medicine , metastasectomy , blockade , surgical oncology , melanoma , immunotherapy , surgery , oncology , immune checkpoint , stage (stratigraphy) , metastasis , cancer , cancer research , receptor , paleontology , biology
Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on to alternative treatments, including surgery, yet the outcome of patients selected for surgery after checkpoint blockade remains unclear.